BCOP Pass Rate, Format & Study Guide

The Board Certified Oncology Pharmacist (BCOP) credential is administered by the Board of Pharmacy Specialties (BPS), which was created on January 5, 1976 as an autonomous division of what was then the American Pharmaceutical Association (now APhA) — making BPS one of the longest-established specialty-certification bodies in pharmacy, and one that's celebrating its 50th anniversary in 2026. BPS certifies pharmacists across more than a dozen recognized specialties, and BCOP specifically validates advanced, specialized competency in oncology pharmacotherapy: managing the complex, high-risk, frequently-changing medication regimens involved in cancer treatment, including chemotherapy dosing, supportive care, and the drug-interaction and toxicity management that generalist pharmacy training doesn't cover in comparable depth.

Oncology pharmacy sits at a uniquely high-stakes intersection of chemotherapy dosing precision, complex drug-interaction management, and rapidly evolving treatment protocols, which is part of why cancer centers, specialty pharmacies, and hospital oncology departments increasingly treat BCOP as an expected credential for pharmacists working directly in oncology care rather than an optional add-on. For pharmacists building a career specifically in oncology — as opposed to general hospital or retail pharmacy — BCOP is often the clearest signal to employers and physician colleagues that a pharmacist has been independently validated on oncology-specific competency, not just accumulated years in a general pharmacy role that happened to touch oncology cases.

BCOP is aimed at licensed pharmacists already working in or transitioning specifically into oncology practice — hospital and cancer-center oncology pharmacists, specialty and infusion-pharmacy pharmacists handling chemotherapy, and pharmacists in oncology-focused clinical or research roles. Given the eligibility pathways require either years of oncology-focused practice or a PGY1/PGY2 residency, it's not a credential a newly licensed pharmacist without oncology-specific training or experience can sit for immediately — it assumes real prior exposure to oncology pharmacy practice.

The certifying body does not publicly publish an official pass rate for this exam. Be wary of third-party sites citing a specific number here — treat any pass-rate claim you see elsewhere for this exam as unverified.

If you don't pass, BPS allows up to two retakes (three attempts total) at a discounted $300 retake fee. There's a mandatory 90-day washout period after each attempt, and once that passes you have another 90 days to schedule and sit for the next try. Fail a third time and you're locked out for 12 months, after which you start over with a new application and the full $600 fee.

BPS scales raw scores onto a 200–800 range, with 500 set as the passing point. The cut score is established through criterion-referenced standard-setting specific to oncology pharmacy — tied to the minimum knowledge a newly certified BCOP needs to have — and a statistical equating process adjusts for difficulty differences between test forms so the passing standard stays consistent across administrations.

The BCOP exam is a 150-item multiple-choice test (125 scored, 25 unscored pretest questions indistinguishable from the scored ones) administered over 3 hours and 45 minutes. BPS scales raw scores onto a 200-800 range with 500 set as the passing point, using a criterion-referenced standard-setting process tied to the minimum knowledge a newly certified BCOP needs — plus statistical equating across exam forms so the passing standard stays consistent even as specific test-form difficulty varies administration to administration.

BPS does not publish a public percentage-weighted domain breakdown for BCOP the way some other boards do — there's no official chart showing "domain X is worth Y%" for candidates to study against directly. Instead, exam content is organized around BPS's official BCOP Examination Content Outline, which spans the core pharmacotherapy areas of oncology practice: solid-tumor and hematologic malignancy treatment regimens, supportive care and toxicity management (nausea, myelosuppression, infection risk, and similar treatment-related complications), pharmacokinetic dosing considerations specific to chemotherapy agents, and the broader patient-safety and medication-management practices unique to high-risk oncology drug therapy. Because there's no official weighting published, most candidates build their study plan directly from the current BCOP Examination Content Outline PDF rather than assuming any particular tumor type or content area dominates.

Candidates need an ACPE-accredited PharmD (or internationally recognized equivalent) degree and a current, active pharmacist license, plus one of three qualifying practice pathways. The first is four years of post-licensure pharmacy practice with at least 50% of that time specifically in oncology pharmacy. The second is completion of a PGY1 (post-graduate year 1) residency plus two additional years of qualifying oncology-focused practice. The third — the fastest pathway — is completion of a PGY2 residency specifically in oncology pharmacy, which on its own satisfies the experience requirement without additional years of independent practice. All three pathways require the oncology-specific focus; general pharmacy practice or a non-oncology residency, on its own, does not qualify regardless of total years worked.

The first-time application and exam fee is $600 USD. If a candidate doesn't pass and needs to retest within the following year, BPS offers a reduced $300 USD retake fee rather than requiring the full $600 again — a meaningfully more forgiving retake structure than several other credentials on this site. There's no separate application fee layered on top of the exam fee the way some certifying bodies charge; the $600 (or $300 retake) figure is the complete cost of sitting for the exam itself.

BCOP recertification structure depends on when your certification began. For BCOP holders certified January 1, 2024 or later, BPS offers two paths: pass a recertification examination (plus self-report up to 20 units of continuing professional development), or complete a professional development program requiring 100 total units over the 7-year recertification cycle — at least 80 of those units from assessed, BPS-approved continuing pharmacy education (CPE) programs, plus up to 20 self-reported continuing professional development (CPD) units. Regardless of which recertification path you're pursuing, BPS also requires a minimum of 2 units of assessed CPE or self-reported CPD reported every single year just to keep the certification in good standing between recertification cycles — you can't defer all continuing education to the end of the 7-year period.

BCOP is 150 questions (125 scored, 25 unscored pretest) in 3 hours 45 minutes, and since scored and pretest items are indistinguishable, there's no way to skip strategically — treat every question as if it counts. BPS doesn't publish a public domain-weighting breakdown for BCOP, so build your prep around the official BCOP Examination Content Outline PDF and budget extra time for whichever tumor-type or supportive-care domain feels furthest from your daily practice.

The most notable real update around BCOP heading into 2026 isn't a change to the exam itself, but to the certifying body: BPS is celebrating its 50th anniversary in 2026 (founded January 5, 1976), a milestone the organization has been actively marking with anniversary programming throughout the year. On the recertification side, BPS's current structure (the 2024-forward path requiring either a recertification exam or the 100-unit/7-year professional development program) reflects a real, dated change from BPS's older recertification rules — if you're referencing older BCOP recertification material, confirm it reflects the current post-2024 structure rather than a retired prior cycle's requirements. No changes to the exam's core 150-question/3-hour-45-minute format have been announced as of August 2026.